Q-omics provides the consensus-scored RAP1GAP profile across patient tissues and cancer cell-line models. RAP1GAP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAP1GAP is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RAP1GAP protein abundance shows 31,117 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where RAP1GAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1GAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1GAP survival associations across molecular data types. RAP1GAP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1GAP RNA expression–survival associations across cancer types. High RAP1GAP expression shows unfavorable associations in UVM, LIHC, LUSC, ACC and SKCM, but favorable associations in COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAP1GAP RNA expression.
This table summarizes RAP1GAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAP1GAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1GAP shows lower tumor expression in THCA, KIRC and KIRP and higher tumor expression in BLCA, BRCA and UCEC. The THCA box plot shows higher RAP1GAP RNA expression in normal versus tumor tissue (log2 FC = −3.371, t-test p < 0.001).
This table shows molecular features associated with RAP1GAP in patient tissues and cancer cell lines. In patient samples, RAP1GAP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAP1GAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
